Drug
Ly3541860
Ly3541860: highest development phase Phase 2, developed by Eli Lilly. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Eli Lilly
Trials
| Drug | Phase | Indication |
|---|---|---|
| LY3541860 NCT06220669 | Phase 2 | Multiple Sclerosis |
Latest
No recent events.
Follow Ly3541860 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.